Tag: roche
-
Roche confident in Alzheimer’s program, despite Lilly flop
Roche said on Wednesday it still believed drugs targeting a protein called beta amyloid had potential to help fight Alzheimer’s disease, despite the high-profile failure of such a product from Eli Lilly. As the setback sent shares in Lilly skidding, Roche pointed out there were significant differences between two experimental Alzheimer’s drugs it was developing…
-
Study finds targeted cancer drugs may work in range of tumor types
By Deena Beasley CHICAGO (Reuters) – Early results from a clinical trial of Roche Holding AG cancer drugs released on Saturday suggest some promise in matching treatments based on abnormalities found in a patient's tumor rather than the organ in which the cancer was originally detected. The findings, presented at the annual meeting of the…
-
Study finds targeted cancer drugs may work in range of tumor types
By Deena Beasley CHICAGO (Reuters) – Early results from a clinical trial of Roche Holding AG cancer drugs released on Saturday suggest some promise in matching treatments based on abnormalities found in a patient's tumor rather than the organ in which the cancer was originally detected. The findings, presented at the annual meeting of the…
-
Roche breast cancer drug Perjeta rejected by NICE
Roche's breast cancer drug Perjeta, or pertuzumab, has been turned down for use on Britain's state health service, making it the latest in a number of pricey new cancer treatments deemed not to offer value for money. The National Institute for Health and Care Excellence (NICE) said in draft guidance on Friday that it could…
-
Roche breast cancer drug Perjeta rejected by NICE
Roche's breast cancer drug Perjeta, or pertuzumab, has been turned down for use on Britain's state health service, making it the latest in a number of pricey new cancer treatments deemed not to offer value for money. The National Institute for Health and Care Excellence (NICE) said in draft guidance on Friday that it could…
-
Factbox: Drugs to watch at Roche, Sanofi and GSK
(Reuters) – GlaxoSmithKline, Roche and Sanofi all hold investor days this week. Below are three new drugs to watch from each company, with consensus annual sales in 2020, according to Thomson Reuters Cortellis. …